Nuvation Bio has achieved a significant milestone with Japan’s approval of IBTROZITM, a key treatment for ROS1-positive lung cancer, marking our commitment to addressing critical needs in oncology. This approval not only expands our global footprint but also reinforces our partnership with Nippon Kayaku, paving the way for enhanced access to innovative therapies in Japan.
NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC). As part of an exclusive license agreement entered in 2023, Nippon Kayaku will commercial
Source: Original Press Release
